Business

Synlait Buys Pokeno Plant – $307m Deal, Net Loss Reduced

Area details
sale Impact Provides “freedom to move forward” and focus on earning the right to grow over the next six months.
Manufacturing issues Multiple “micro” issues across engineering,plants,people,and processes – not a single major problem. These were “one-offs”.
cost Implications Issues in advanced nutrition production quickly increase costs and require support for customers.
a2 Milk Relationship Trade with a2 Milk (Synlait’s biggest customer) was *not* hindered by the issues. Synlait is currently a2 Milk’s sole infant formula supplier.
a2 Milk’s Future Manufacturing a2 Milk is becoming its own manufacturer with the purchase of Yashili’s plant in Pōkeno for $282m.
SAMR Registration Synlait has registration from china’s SAMR to produce China label formula for a2 Milk,renewable in 2027.
Production Shift a2 Milk’s new plant will likely handle Synlait’s English label product, but Synlait may still have opportunities to produce it.
Debt Status Synlait is on track to be debt-free by the end of 2026.
Future Investment The board is expected to be cautious about future investments. CEO would advocate for a debt equity ratio of 20-25%.
Sharemarket Reaction Synlait shares increased 11.5c to 81.5c following the sale proclamation.
Sale Significance The sale to Abbott (an existing major customer) is considered a “defining moment” for Synlait.